Peptide Library
Retatrutide
Retatrutide (GLP-3 agonist)
Investigational triple agonist (GLP-1 / GIP / glucagon) studied for weight management. NOT FDA-approved.
Baseline Labs Generally Required
Educational page only. Retatrutide is investigational and not FDA-approved. Under current FDA policy it cannot be used in compounding for individual patients. View available therapies →
Quick Answer
Retatrutide is Investigational triple agonist (GLP-1 / GIP / glucagon) studied for weight management. NOT FDA-approved. Whether it is appropriate depends on your medical history, goals, current medications, and testing — evaluated by a licensed VidaVital Medical provider during a live consultation. Educational content only; not medical advice.
Key Takeaways
- Retatrutide is an educational topic currently being studied.
- Baseline labs are generally required before a provider considers this therapy.
- Providers may evaluate it in weight-management, metabolic-health.
- A licensed VidaVital provider must complete a live consultation before any treatment is prescribed.
What is it?
Investigational triple agonist (GLP-1 / GIP / glucagon) studied for weight management. NOT FDA-approved. A licensed provider reviews suitability, monitoring, and any needed testing during a live consultation.
What may it support?
- Weight management research
- Metabolic support
Where might it fit?
intermediate pathwayadvanced pathwayweight managementmetabolic health
Bloodwork & monitoring
Baseline status
Baseline Labs Generally Required
Common tests
- CMP
- CBC
- Lipid panel
The provider determines follow-up cadence individually.
The provider determines final requirements.
Potential side effects
- Injection-site reaction
- Mild GI discomfort
- Rare allergic reaction
Who may not be a candidate?
- • Pregnancy
- • Active malignancy without oncology clearance
Drug interactions
- • Providers review all medications during consultation
Regulatory disclosures
This therapy has limited clinical evidence or may be investigational. Availability may be restricted, and inclusion on this website does not mean that VidaVital Medical currently prescribes or dispenses it.
Frequently asked questions
Do I need bloodwork first?
Your provider decides during your live consultation.
Will VidaVital prescribe this to me?
Only if a licensed provider determines it is medically appropriate after a full evaluation.
Sources
- Provider-reviewed clinical summary — reviewed 2026-01-15 by VidaVital Medical
Related therapies
Semaglutide
A GLP-1 receptor agonist commonly evaluated for medical weight management and metabolic support.
Baseline Labs Generally Required
Tirzepatide
Dual GIP/GLP-1 receptor agonist evaluated for weight and cardiometabolic health.
Baseline Labs Generally Required
AOD-9604
Modified GH fragment studied for lipolysis in research settings.
Provider Determines Testing
The information on this website is for educational purposes and does not constitute medical advice, diagnosis, or a prescription. Treatment eligibility, medication selection, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed medical provider after a live consultation and review of the patient's medical history.